When analyzing the DNMT3A, TET2, and ASXL1 CH-mutations individually, patients with persistent mutations in TET2 and DNMT3A mutations had similar survival outcomes to patients without CH, while patients with persistent ASXL1 mutations showed a non-significant trend toward better outcomes than patients without CH in the respective gene. This evidence concerns the gene TET2 and cyclic hematopoiesis.